Kiora Pharmaceuticals
KPRX
5 hedge funds and large institutions have $575K invested in Kiora Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
17% less funds holding
Funds holding: 6 → 5 (-1)
45% less capital invested
Capital invested by funds: $1.04M → $575K (-$464K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$507K |
| 2 |
SSG
Summit Securities Group
New York
|
-$17K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $314K | -$507K | -58 | -62% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $204K | +$78.6K | +9 | +64% |
|
|
IA
3
IFP Advisors
Tampa,
Florida
| $22K | – | – | – |
|
|
BFA
4
BlackRock Fund Advisors
San Francisco,
California
| $17K | – | – | – |
|
|
VIA
5
Vantage Investment Advisors
State College,
Pennsylvania
| $11K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $4K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
BIM
8
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
|
SSG
10
Summit Securities Group
New York
| – | -$17K | -2 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$2K | – | – |
|
KPRX Hedge Fund Activity: Q4 2016 in Review
5 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2016, worth a combined $575K — down 45% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of KPRX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $78.6K. The largest seller was Sabby Management, cutting an estimated $507K.
- 5 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2016, down from 6 in Q3 2016.
- Funds reported $575K of Kiora Pharmaceuticals stock for Q4 2016, down 45% quarter-over-quarter.
- 0 funds opened new Kiora Pharmaceuticals positions in Q4 2016 and 1 closed out, a net change of -1 holder.
- The largest Kiora Pharmaceuticals buyer in Q4 2016 was Vanguard Group, an estimated $78.6K added.
- The largest Kiora Pharmaceuticals seller in Q4 2016 was Sabby Management, an estimated $507K sold.
Based on aggregated 13F filings for Q4 2016.